Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy.

Authors: Lau, E; Sedy, J; Sander, C; Shaw, M A; Feng, Y; Scortegagna, M; Claps, G; Robinson, S; Cheng, P; Srivas, R; Soonthornvacharin, S; Ideker, T; Bosenberg, M; Gonzalez, R; Robinson, W; Chanda, S K; Ware, C; Dummer, R; Hoon, D; Kirkwood, J M; Ronai, Z A

Published In Oncogene, (2015 Nov 12)

Abstract: The resistance of melanoma to current treatment modalities represents a major obstacle for durable therapeutic response, and thus the elucidation of mechanisms of resistance is urgently needed. The crucial functions of activating transcription factor-2 (ATF2) in the development and therapeutic resistance of melanoma have been previously reported, although the precise underlying mechanisms remain unclear. Here, we report a protein kinase C-ɛ (PKCɛ)- and ATF2-mediated mechanism that facilitates resistance by transcriptionally repressing the expression of interferon-β1 (IFNβ1) and downstream type-I IFN signaling that is otherwise induced upon exposure to chemotherapy. Treatment of early-stage melanomas expressing low levels of PKCɛ with chemotherapies relieves ATF2-mediated transcriptional repression of IFNβ1, resulting in impaired S-phase progression, a senescence-like phenotype and increased cell death. This response is lost in late-stage metastatic melanomas expressing high levels of PKCɛ. Notably, nuclear ATF2 and low expression of IFNβ1 in melanoma tumor samples correlates with poor patient responsiveness to biochemotherapy or neoadjuvant IFN-α2a. Conversely, cytosolic ATF2 and induction of IFNβ1 coincides with therapeutic responsiveness. Collectively, we identify an IFNβ1-dependent, cell-autonomous mechanism that contributes to the therapeutic resistance of melanoma via the PKCɛ-ATF2 regulatory axis.

PubMed ID: 25728676 Exiting the NIEHS site

MeSH Terms: Activating Transcription Factor 2/metabolism*; Cell Line, Tumor; Cell Nucleus/metabolism; Down-Regulation; Drug Resistance, Neoplasm*; Humans; Interferon-beta/genetics*; Melanoma/drug therapy; Melanoma/genetics*; Melanoma/metabolism; Melanoma/pathology; Promoter Regions, Genetic; Protein Kinase C-epsilon/metabolism; Signal Transduction; Transcription, Genetic

to Top